Alaunos Therapeutics (TCRT) Total Liabilities (2009 - 2026)
Alaunos Therapeutics' (TCRT) quarterly Total Liabilities came in at $595000.0 in Q1 2026, down 43.97% YoY from $1.1 million in Q1 2025, and down 26.81% on a QoQ basis from $813000.0 in Q4 2025.
Alaunos Therapeutics (TCRT) Total Liabilities (2009 - 2026) Analysis & Trends
Alaunos Therapeutics (TCRT) has 18 years of Total Liabilities data on file, last reported at $595000.0 in Q1 2026.
- Quarterly Total Liabilities fell 43.97% year-over-year to $595000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $595000.0 (down 43.97% YoY) and the FY2025 annual result came in at $813000.0, up 17.49% from the prior year.
- Total Liabilities slipped to $595000.0 in Q1 2026, from $813000.0 in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $35.9 million in Q1 2022 to a low of $595000.0 in Q1 2026.
- A 5-year average of $10.1 million and a median of $1.2 million in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities surged 82.6% — and 2024, when it slumped 93.52%.
- Tracing TCRT's Total Liabilities over 5 years: stood at $26.4 million in 2022, then tumbled by 92.59% to $2.0 million in 2023, then slumped by 64.62% to $692000.0 in 2024, then increased by 17.49% to $813000.0 in 2025, then decreased by 26.81% to $595000.0 in 2026.
- The last three Total Liabilities figures came in at $595000.0 (Q1 2026), $813000.0 (Q4 2025), and $921000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.72 Bn | 77.73 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 10.03 Bn |
| 10 | Alaunos Therapeutics | 4.26 Mn | 4.13 Mn | - | 864,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 595,000.00 |
| Dec 31, 2025 | 813,000.00 |
| Sep 30, 2025 | 921,000.00 |
| Jun 30, 2025 | 1.07 Mn |
| Mar 31, 2025 | 1.06 Mn |
| Dec 31, 2024 | 692,000.00 |
| Sep 30, 2024 | 826,000.00 |
| Jun 30, 2024 | 907,000.00 |
| Mar 31, 2024 | 1.24 Mn |
| Dec 31, 2023 | 1.96 Mn |
| Sep 30, 2023 | 5.54 Mn |
| Jun 30, 2023 | 6.28 Mn |
| Mar 31, 2023 | 19.13 Mn |
| Dec 31, 2022 | 26.38 Mn |
| Sep 30, 2022 | 35.23 Mn |
| Jun 30, 2022 | 33.75 Mn |
| Mar 31, 2022 | 35.87 Mn |
| Dec 31, 2021 | 36.81 Mn |
| Sep 30, 2021 | 45.06 Mn |
| Jun 30, 2021 | 18.48 Mn |